Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression
Cancer Cell · 2025-10 · 43 (10) · 1885-1901.e10
DOI: 10.1016/j.ccell.2025.07.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2025-10. Verfasst von Mingxu Xie und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Healt…. Hauptthemen laut MEDLINE: Clostridium butyricum, Colorectal Neoplasms, Probiotics, Interleukin-6. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Innovation and Technology Fund, National Key Research and Development Program of China Stem Cell and Translational Research.
Abstract (Originalsprache)
Most colorectal cancer (CRC) patients do not respond to immune checkpoint blockade (ICB) therapy. Here, we identify Clostridium butyricum as a probiotic that boosts anti-PD-1 efficacy in CRC. In orthotopic allografts of microsatellite instability-high (MSI-H) and microsatellite stable (MSS) CRC, C. butyricum potentiates tumor suppressive effect of anti-PD-1, which is verified in AOM/DSS-induced CRC and germ-free mice. Single-cell RNA-seq reveals that C. butyricum activates cytotoxic CD8+ T lymphocytes (CTLs) and impairs tumor-associated macrophages (TAMs), especially in conjunction with anti-PD-1. Mechanistically, C. butyricum surface protein secD binds to CRC cell receptor glucose-regulated protein 78 (GRP78), which inactivates GRP78 and PI3K-AKT-NF-κB pathway, leading to reduced secretion of interleukin (IL)-6, an immunosuppressive cytokine that blunts CTLs and induces TAMs. Translational impact of C. butyricum in boosting anti-PD-1 efficacy is validated in huCD34+ humanized mice and autologous patient-derived CRC organoids-CTLs co-culture system. To summarize, C. butyricum is a promising adjuvant to augment ICB therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK-Shenzhen Research Institute, The Chinese University o…
- Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Förderung
- National Key Research and Development Program of China
- Innovation and Technology Fund
- National Key Research and Development Program of China Stem Cell and Translational Research
- Chinese University of Hong Kong
Zitieren
APA
Xie, M., Yuan, K., Zhang, Y., Zhang, Y., Zhang, R., Gao, J., Wei, W., Jiang, L., Li, T., Ding, Y., Wang, L., Lin, Y., Wong, C. C., & Yu, J. (2025). Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. Cancer Cell, 43(10), 1885-1901.e10. https://doi.org/10.1016/j.ccell.2025.07.012
Vancouver
Xie M, Yuan K, Zhang Y, Zhang Y, Zhang R, Gao J, et al. Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. Cancer Cell. 2025;43(10):1885-1901.e10. doi:10.1016/j.ccell.2025.07.012
BibTeX
@article{Xie2025,
author = {Xie, Mingxu and Yuan, Kai and Zhang, Yongxin and Zhang, Yating and Zhang, Ruyi and Gao, Jiuhe and Wei, Wenchao and Jiang, Lanping and Li, Tianhui and Ding, Yanqiang and Wang, Luyao and Lin, Yufeng and Wong, Chi Chun and Yu, Jun},
title = {Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression},
journal = {Cancer Cell},
year = {2025},
volume = {43},
number = {10},
pages = {1885--1901.e10},
doi = {10.1016/j.ccell.2025.07.012}
}
EUVIMED